Sugi Predict

Sugi Predict / Compounds / SCHEMBL14925849

SCHEMBL14925849

SCHEMBL14925849

C[C@H]1CN(C(=O)OC(C)(C)C)CCN1c1ccc([N+](=O)[O-])nc1

nearest known ligand 0.50

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ GPR119 Q8TDV5 11/20 0.50
▸ MAPT P10636 4/20 0.49
▸ LMNA P02545 2/20 0.49
▸ ALDH1A1 P00352 1/20 0.49
▸ RAB9A P51151 1/20 0.46
▸ SMARCA2 P51531 1/20 0.44
▸ SMARCA4 P51532 1/20 0.44
▸ PBRM1 Q86U86 1/20 0.44
▸ MET P08581 2/20 0.43
▸ TP53 P04637 1/20 0.43
▸ THRB P10828 1/20 0.43
▸ CHRNB2 P17787 1/20 0.43
▸ CHRNA4 P43681 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29731850 1.00 GPR119 (0.50) GPR119MAPTLMNAALDH1A1RAB9A
SCHEMBL29741983 1.00 GPR119 (0.50) GPR119MAPTLMNAALDH1A1RAB9A
SCHEMBL14924375 1.00 GPR119 (0.50) GPR119MAPTLMNAALDH1A1RAB9A
SCHEMBL30512281 1.00 GPR119 (0.50) GPR119MAPTLMNAALDH1A1RAB9A
SCHEMBL22802474 1.00 GPR119 (0.50) GPR119MAPTLMNAALDH1A1RAB9A
SCHEMBL29741999 0.87 MAPT (0.47) GPR119MAPTLMNAALDH1A1RAB9A
SCHEMBL14924381 0.87 MAPT (0.47) GPR119MAPTLMNAALDH1A1RAB9A
SCHEMBL30578916 0.87 MAPT (0.47) GPR119MAPTLMNAALDH1A1RAB9A
SCHEMBL27965768 0.87 MAPT (0.47) GPR119MAPTLMNAALDH1A1RAB9A
SCHEMBL28855389 0.86 GPR119 (0.48) GPR119MAPTLMNAALDH1A1SMARCA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250136620-A1 BTK DEGRADER NEWAVE PHARMACEUTICAL INC. 2025-05-01 — — US disclosed
EP-4055019-B1 BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY NURIX THERAPEUTICS INC (US) 2025-01-22 — — EP disclosed
CN-117897388-A BTK protein degradation agent 广州麓鹏制药有限公司 2024-04-16 — — CN disclosed
US-20240058457-A1 BTK DEGRADER NEWAVE PHARMACEUTICAL INC. (US) 2024-02-22 — — US disclosed
US-20230348471-A1 BRUTON'S TYROSINE KINASE INHIBITOR AND PREPARATION METHOD THEREFOR ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD. (CN) 2023-11-02 — — US disclosed
US-20230279012-A1 HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS GENENTECH, INC. (US) 2023-09-07 — — US disclosed
US-20230250103-A1 PROCESS FOR PREPARING BTK INHIBITORS GENENTECH, INC. (US) 2023-08-10 — — US disclosed
WO-2023137225-A1 BTK DEGRADER NEWAVE PHARMACEUTICAL INC. (US) 2023-07-20 — — WO disclosed
US-11661424-B2 Process for preparing BTK inhibitors GENENTECH, INC. (US) 2023-05-30 — — US disclosed
CN-115785097-A BTK inhibitor and application thereof 乳源东阳光药业有限公司 2023-03-14 — — CN disclosed
US-8716274-B2 Heteroaryl pyridone and aza-pyridone compounds GENENTECH, INC. (US) 2014-05-06 — — US disclosed
US-8716274-B2 Heteroaryl pyridone and aza-pyridone compounds GENENTECH, INC. (US) 2014-05-06 — — US disclosed
US-8669251-B2 8-fluorophthalazin-1(2H)-one compounds GENENTECH, INC. (US) 2014-03-11 — — US disclosed
US-8669251-B2 8-fluorophthalazin-1(2H)-one compounds GENENTECH, INC. (US) 2014-03-11 — — US disclosed
WO-2013067274-A1 HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS AS INHIBITORS OF BTK ACTIVITY GENENTECH, INC. (US) 2013-05-10 — — WO disclosed
US-20130116235-A1 HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS GENENTECH, INC. (US) 2013-05-09 — — US disclosed
US-20130116246-A1 8-FLUOROPHTHALAZIN-1(2H)-ONE COMPOUNDS GENENTECH, INC. (US) 2013-05-09 — — US disclosed
US-20130116246-A1 8-FLUOROPHTHALAZIN-1(2H)-ONE COMPOUNDS GENENTECH, INC. (US) 2013-05-09 — — US disclosed
US-20130116235-A1 HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS GENENTECH, INC. (US) 2013-05-09 — — US disclosed
US-20130116245-A1 ALKYLATED PIPERAZINE COMPOUNDS GENENTECH, INC. (US) 2013-05-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230250103-A1 PROCESS FOR PREPARING BTK INHIBITORS BTK, SYK, LYN GPR119 4259/4885MAPT 3903/4885LMNA 3033/4885
US-11661424-B2 Process for preparing BTK inhibitors BTK, SYK, LYN GPR119 4259/4885MAPT 3903/4885LMNA 3033/4885
US-20130116246-A1 8-FLUOROPHTHALAZIN-1(2H)-ONE COMPOUNDS BTK, LCK, SYK GPR119 3309/4885MAPT 1436/4885LMNA 2079/4885
US-20230348471-A1 BRUTON'S TYROSINE KINASE INHIBITOR AND PREPARATION METHOD THEREFOR BTK, SYK, LCK GPR119 2417/4885MAPT 4647/4885LMNA 2975/4885
US-20240058457-A1 BTK DEGRADER BTK, LYN, SYK GPR119 2801/4885MAPT 3930/4885LMNA 4441/4885
US-20130116245-A1 ALKYLATED PIPERAZINE COMPOUNDS BTK, SYK, LCK GPR119 2141/4885MAPT 1919/4885LMNA 3577/4885
US-20230279012-A1 HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS PDXK, BTK, TYK2 GPR119 2921/4885MAPT 2050/4885LMNA 2651/4885
US-20130116235-A1 HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS BTK, PDXK, TYK2 GPR119 3004/4885MAPT 3237/4885LMNA 1756/4885
US-20250136620-A1 BTK DEGRADER BTK, CBL, LYN GPR119 3109/4885MAPT 2504/4885LMNA 4410/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.